FDA's DDMAC Letter Says Sanofi-Aventis Materials Need Latest Risk Information
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency reiterates that risk information must be included on every page with a promotional claim in letter to Sanofi-Aventis.